Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 337
- Registration Number
- NCT04270409
- Locations
- 🇦🇺
Investigational Site Number :0360008, Liverpool, New South Wales, Australia
🇯🇵Investigational Site Number :3920001, Shibuya-ku, Tokyo, Japan
🇱🇹Investigational Site Number :4400001, Vilnius, Lithuania
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 160
- Registration Number
- NCT04202679
- Locations
- 🇨🇦
Investigational Site Number :1240006, Surrey, British Columbia, Canada
🇨🇱Investigational Site Number :1520006, Osorno, Reg Metropolitana De Santiago, Chile
🇭🇺Investigational Site Number :3480005, Pécs, Hungary
Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 105
- Registration Number
- NCT04191382
- Locations
- 🇺🇸
Investigational Site Number 8400010, Los Angeles, California, United States
🇺🇸Investigational Site Number 8400005, Lincoln, Nebraska, United States
🇺🇸Investigational Site Number 8400012, Tacoma, Washington, United States
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 151
- Registration Number
- NCT04183335
- Locations
- 🇺🇸
Investigational Site Number :8400001, Dublin, Ohio, United States
🇺🇸Investigational Site Number :8400025, Houston, Texas, United States
🇺🇸Investigational Site Number :8400011, Gilbert, Arizona, United States
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 397
- Registration Number
- NCT04180488
- Locations
- 🇺🇸
Allergy & Asthma Specialists, PSC Site Number : 8400020, Owensboro, Kentucky, United States
🇺🇸Johns Hopkins University (Asthma and Allergy Center) Site Number : 8400016, Baltimore, Maryland, United States
🇺🇸Allergy and Clinical Immunology Associates Site Number : 8400024, Pittsburgh, Pennsylvania, United States
Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT04171310
- Locations
- 🇬🇧
Investigational Site Number 8260001, Nottingham, United Kingdom
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 389
- Registration Number
- NCT04154956
- Locations
- 🇮🇳
Investigational Site Number : 3560011, Trivandrum, India
🇺🇸National Jewish Health Site Number : 8400033, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists South Division Site Number : 8400020, Fort Myers, Florida, United States
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT04143958
A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)
- Conditions
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT04106544
- Locations
- 🇧🇷
Investigational Site Number :0760001, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇷Investigational Site Number :0320002, Caba, Argentina
🇹🇷Investigational Site Number :7920001, Izmir, Turkey
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 343
- Registration Number
- NCT04075513
- Locations
- 🇬🇧
Investigational site United Kingdom, United Kingdom, United Kingdom
🇭🇺Investigational site Hungary, Hungary, Hungary
🇺🇸United States, Dallas, Texas, United States